Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial to Evaluate the Safety and Efficacy of iPSC-Derived Dopaminergic Progenitors in the Treatment of Parkinson's Disease

Next Previous
X
Search
Trial Profile

A Phase I/II Trial to Evaluate the Safety and Efficacy of iPSC-Derived Dopaminergic Progenitors in the Treatment of Parkinson's Disease

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CT1 DAP001/DSP 1083 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 10 Aug 2018 New trial record
    • 30 Jul 2018 According to a Kyoto University media release and announcement posted on CiRAs website, Kyoto University Hospital, in partnership with the Center for iPS Cell Research and Application (CiRA), Kyoto University, has planned physician-initiated clinical trials (this and phase III trial) for Parkinson's disease that transplants dopaminergic progenitors generated from induced pluripotent stem (iPS) cells.
    • 30 Jul 2018 According to a Kyoto University media release and announcement posted on CiRAs website, the clinical trial notification was submitted to the Pharmaceutical and Medical Devices Agency on 4 Jun 2018 and the clinical trials (this and phase III trial) are scheduled to begin on 1 Aug 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top